Windsor Capital Management LLC Buys 2,117 Shares of Amgen Inc. $AMGN

Windsor Capital Management LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 132.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,710 shares of the medical research company’s stock after purchasing an additional 2,117 shares during the period. Windsor Capital Management LLC’s holdings in Amgen were worth $1,214,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of AMGN. Sequoia Financial Advisors LLC grew its stake in shares of Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after acquiring an additional 3,619 shares during the last quarter. Davis Capital Management acquired a new position in Amgen during the 3rd quarter valued at $1,841,000. D.A. Davidson & CO. boosted its holdings in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares during the period. Global Wealth Management Investment Advisory Inc. grew its position in Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after purchasing an additional 4,699 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of Amgen by 18.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after purchasing an additional 6,115 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $349.00 on Tuesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The business’s fifty day moving average price is $362.96 and its two-hundred day moving average price is $331.05. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a market capitalization of $188.14 billion, a price-to-earnings ratio of 24.53, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s payout ratio is 70.84%.

Analyst Ratings Changes

AMGN has been the subject of several research reports. HSBC reiterated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. UBS Group boosted their price objective on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Rothschild & Co Redburn raised their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Piper Sandler boosted their price target on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.